In a retrospective chart review, we assessed the efficacy and safety of GLP1/GIP agonists, specifically tirzepatide, in managing Type 1 Diabetes (T1D). The study involved 15 patients (7 males, 8 females; average age 48 years; average diabetes duration 34 years), using Continuous Glucose Monitors (CGM). Among them, 8 on insulin pumps and 7 Multiple Daily Injections (MDI). Six had prior exposure to GLP1 agonists. The intervention, recognized as off-label, included careful insulin titration and ketone monitoring. Over 6-12 months, significant findings emerged: A1c levels significantly decreased at 6 months (Cohen's d = -0.79), indicating short-term effectiveness, but this change wasn't sustained at 1 year, suggesting the need for ongoing or modified approaches for long-term glycemic control. Additionally, there was a reduction in average Body Mass Index (BMI) with baseline 34.7, 6 month 31.7, 1 year 28.9 (Box and Whisker availble) and insulin requirements (attached) at both intervals, reflecting improved metabolic health and insulin sensitivity. Risks were mitigated through strategic insulin reduction. However, one patient discontinued due to severe hypoglycemia despite these adjustments. Mild nausea and constipation were reported in 3 patients. These findings, while preliminary, highlight the potential benefits of GLP1/GIP agonists in T1D management, warranting further investigation despite the risk of hypoglycemia and other side effects.
B.P. Childs: Research Support; Abbott. Advisory Panel; Provention Bio, Inc. M. Tade: None. J. Sebes: None. L. Molt: None. A. Childs: None.
